Volume calculations for current intravitreal injections of Lucentis®;Volumenberechnungen zur aktuellen intravitrealen Injektion von Lucentis® Lucentis

Ophthalmologe

Volumn 107, Issue 5, 2010, Pages 435-438

  Wolf, A ^a   Gandorfer, A ^a   Haritoglou, C ^a   Koller, C ^b   Thalmeier, A ^a   Kampik, A ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Kanzlei Tacke Krafft   (Germany)

Author keywords

AMD; Divisibility; Intravitreal injection; Lucentis ; Own pack dispensing

Indexed keywords

ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; RANIBIZUMAB;

ARTICLE; COMPUTER ASSISTED DRUG THERAPY; DRUG EFFECT; HUMAN; INJECTION; METHODOLOGY; NEOVASCULAR GLAUCOMA; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMPUTER-ASSISTED; GLAUCOMA, NEOVASCULAR; HUMANS; INJECTIONS; VITREOUS BODY;

EID: 77952428015     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-009-2060-8     Document Type: Article

References (6)

1. Boyer DS, Antoszyk AN, MARINA Study Group et al (2007) Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114: 246-252.
2. Diabetic Retinopathy Clinical Research Network (2008) A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 115: 1447-1449, 1449. e1-1449. e10.
3. Kaiser PK, Brown DM, Zhang K et al (2007) Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 144: 850-857.
4. Rosenfeld PJ, Brown DM, Heier JS, MARINA Study Group et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431.
5. Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36: 331-335.
6. VEGF Inhibition Study in Ocular Neovascularization (V. I. S. I. O. N.) Clinical Trial Group, Chakravarthy U, Adamis AP et al (2006) Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 113: 1508. e1-1508. e25.